Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis.

Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis. Journal of scleroderma and related disorders Valenzuela, A., Chung, L., Pauling, J. D., Domsic, R., Saketkoo, L., Fligelstone, K., Russell, A. M., Khanna, D., Frech, T., Ross, L., Nikpour, M., Denton, C., Baron, M. 2026; 11 (1): e000009

Abstract

The Scleroderma Clinical Trials Consortium (SCTC) is committed to advancing the understanding and treatment of systemic sclerosis (SSc). This review focuses on the development and validation of various outcome instruments by the SCTC, which are crucial for evaluating the effectiveness of interventions in clinical trials and observational studies. Key instruments discussed include the Assessment of Systemic Sclerosis-Associated RAynaud's Phenomenon Questionnaire, the SCTC Radiologic Scoring System for calcinosis, the Mawdsley Questionnaire for calcinosis, the University of California Los Angeles SCTC Gastrointestinal Tract Instrument (GIT) 2.0, the SCTC Activity Index and the SCTC Damage Index. Additionally, the SCTC and World Scleroderma Foundation (WSF) Skin Scoring Certification is highlighted as an important resource for researchers. Each instrument's purpose, description and validation process are examined, underscoring their pivotal role in advancing SSc research and improving patient outcomes.

View details for DOI 10.1136/jsrd-2026-000009

View details for PubMedID 42256631

View details for PubMedCentralID PMC13231724